- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting tyrosine-kinases in ovarian cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 22, Issue 10, Pages 1265-1279
Publisher
Informa Healthcare
Online
2013-07-02
DOI
10.1517/13543784.2013.816282
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCG study.
- (2017) Ignace B. Vergote et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted anti-vascular therapies for ovarian cancer: current evidence
- (2013) M Hall et al. BRITISH JOURNAL OF CANCER
- EGFR Gene Copy Number as a Prognostic Marker in Colorectal Cancer Patients Treated with Cetuximab or Panitumumab: A Systematic Review and Meta Analysis
- (2013) Zheng Jiang et al. PLoS One
- A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy
- (2012) K. H. Baumann et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A Phase I Trial of Dasatinib, an Src-Family Kinase Inhibitor, in Combination with Paclitaxel and Carboplatin in Patients with Advanced or Recurrent Ovarian Cancer
- (2012) A. A. Secord et al. CLINICAL CANCER RESEARCH
- Adjuvant Therapy of Gastrointestinal Stromal Tumors (GIST)
- (2012) Paolo G. Casali et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Perspective: Dynamics of receptor tyrosine kinase signaling complexes
- (2012) Bruce J. Mayer FEBS LETTERS
- Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
- (2012) Russell J. Schilder et al. GYNECOLOGIC ONCOLOGY
- Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube
- (2012) Ignacio Romero Noguera et al. GYNECOLOGIC ONCOLOGY
- A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma
- (2012) Susana M. Campos et al. GYNECOLOGIC ONCOLOGY
- Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment
- (2012) Bryan P Schneider et al. LANCET ONCOLOGY
- A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
- (2012) King Pan Ng et al. NATURE MEDICINE
- The PACOVAR-trial: A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer
- (2011) Michael Eichbaum et al. BMC CANCER
- Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer
- (2011) F A Raja et al. BRITISH JOURNAL OF CANCER
- The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer
- (2011) Q Sheng et al. BRITISH JOURNAL OF CANCER
- Recent progress in the diagnosis and treatment of ovarian cancer
- (2011) Danijela Jelovac et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib
- (2011) Jenny J. Kim et al. CANCER
- Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer
- (2011) Samar Masoumi Moghaddam et al. CANCER AND METASTASIS REVIEWS
- Targeting angiogenesis in ovarian cancer
- (2011) Jordan Schmitt et al. CANCER TREATMENT REVIEWS
- Biomarkers in the development of anti-angiogenic therapies for ovarian cancer
- (2011) Fharat A. Raja et al. CANCER TREATMENT REVIEWS
- Mechanisms of drug resistance in kinases
- (2011) Rina Barouch-Bentov et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: A phase II study
- (2011) Lubomir Bodnar et al. GYNECOLOGIC ONCOLOGY
- Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group
- (2011) R. Ramasubbaiah et al. GYNECOLOGIC ONCOLOGY
- Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma
- (2011) S. John Weroha et al. GYNECOLOGIC ONCOLOGY
- A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study
- (2011) Agustin A. Garcia et al. GYNECOLOGIC ONCOLOGY
- Pazopanib Efficacy in Renal Cell Carcinoma: Evidence for Predictive Genetic Markers in Angiogenesis-Related and Exposure-Related Genes
- (2011) Chun-Fang Xu et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer
- (2011) Jonathan A. Ledermann et al. JOURNAL OF CLINICAL ONCOLOGY
- Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
- (2011) Jesus Garcia-Donas et al. LANCET ONCOLOGY
- Taming the dragon: genomic biomarkers to individualize the treatment of cancer
- (2011) Ian J Majewski et al. NATURE MEDICINE
- Immunohistochemical expression of epidermal growth factor receptor, E-cadherin, and matrix metalloproteinase–9 in ovarian epithelial cancer and relation to patient deaths
- (2010) Hanan AlSaeid Alshenawy Annals of Diagnostic Pathology
- EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer
- (2010) I. J. Dahabreh et al. ANNALS OF ONCOLOGY
- A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
- (2010) J. J. Biagi et al. ANNALS OF ONCOLOGY
- Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer
- (2010) Martin Pölcher et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Overexpression of Tumor Vascular Endothelial Growth Factor A May Portend an Increased Likelihood of Progression in a Phase II Trial of Bevacizumab and Erlotinib in Resistant Ovarian Cancer
- (2010) S. K. Chambers et al. CLINICAL CANCER RESEARCH
- Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2
- (2010) C. M. Annunziata et al. CLINICAL CANCER RESEARCH
- Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer
- (2010) Ernest S. Han et al. GYNECOLOGIC ONCOLOGY
- Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074)
- (2010) Patricia Pautier et al. GYNECOLOGIC ONCOLOGY
- A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149)
- (2010) H. Hirte et al. GYNECOLOGIC ONCOLOGY
- Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment
- (2010) Stephanie V. Blank et al. GYNECOLOGIC ONCOLOGY
- A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
- (2010) Michael Friedlander et al. GYNECOLOGIC ONCOLOGY
- Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer
- (2010) Stephen A. Welch et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial
- (2010) Daniela Matei et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel Agents on the Horizon for Cancer Therapy
- (2009) W. W. Ma et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Clinical pharmacokinetics of tyrosine kinase inhibitors
- (2009) Nielka P. van Erp et al. CANCER TREATMENT REVIEWS
- Angiogenesis and ovarian cancer
- (2009) César Gómez-Raposo et al. Clinical & Translational Oncology
- Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
- (2009) Ursula A. Matulonis et al. JOURNAL OF CLINICAL ONCOLOGY
- Ovarian cancer
- (2009) Bryan T Hennessy et al. LANCET
- A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
- (2008) P A Vasey et al. BRITISH JOURNAL OF CANCER
- Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis
- (2008) Daniela Matei et al. CANCER
- Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data
- (2008) J. R. Molina et al. CLINICAL CANCER RESEARCH
- Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia
- (2008) Halla S. Nimeiri et al. GYNECOLOGIC ONCOLOGY
- A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma
- (2008) Kristopher J. Kimball et al. GYNECOLOGIC ONCOLOGY
- Dual-Agent Molecular Targeting of the ErbB2 Receptor: Killing One Bird With Two Stones
- (2008) Hal W. Hirte et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Evaluation of Imatinib Mesylate in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study
- (2008) Russell J. Schilder et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity
- (2008) Nilofer S. Azad et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Angiogenesis
- (2008) Robert S. Kerbel NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started